Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glycogen synthase kinase 3 beta (GSK3β) and casein kinase 1 alpha (CK1α) are serine/threonine protein kinases—enzymes that act as phosphotransferases—central to the canonical Wnt/β-catenin signaling pathway. In the absence of Wnt signaling, they phosphorylate β-catenin within the destruction complex (which includes Axin and APC), marking β-catenin for ubiquitination and proteasomal degradation. Upon Wnt ligand binding to Frizzled and LRP5/6 receptors, recruitment and phosphorylation events alter the complex, suppressing GSK3β/CK1α action on β-catenin, thereby allowing β-catenin stabilization, nuclear translocation, and transactivation of Wnt-responsive genes crucial for proliferation, differentiation, development, and stem cell maintenance. Dysregulation of these kinases is strongly implicated in cancer and other diseases[1][2][4][5][7].
Inhibition of β-catenin phosphorylation and degradation (GSK3β/CK1α inhibitors) Activation/suppression of downstream Wnt target gene transcription
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glycogen synthase kinase 3 beta (GSK3β) and Casein kinase 1 alpha (CK1α) (GSK3β, CK1α).